PF‐03446962‐mediated inhibition of ALK1 signaling was expected to disrupt tumor angiogenesis and inhibit tumor growth when administered as monotherapy, based on the results obtained in preclinical studies 15. The gene discussed is ACVRL1; the disease is neoplasm.